Hypertensive cerebral hemorrhage with undetectable plasma VEGF after
intravitreal injection of aflibercept for diabetic macular edema
Anti-vascular endothelial growth factor (VEGF) therapy is widely used to
maintain visual functioning in macular diseases including diabetic
macular edema (DME). We report a case of a hypertensive cerebral
hemorrhage even after intravitreal injections of aflibercept for DME in
which the patient’s plasma VEGF levels were below the detection limit.